Xiaojuan Wu1, Bei Cai1, Zhenzhen Su1, Yamei Li1, Jin Xu1, Rong Deng2, Lanlan Wang1. 1. Department of Laboratory Medicine/Research Center of Clinical Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. 2. Department of Infectious Disease Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Abstract
BACKGROUND: The benefits of using serum markers to diagnose stages of liver disease in chronic hepatitis B (CHB) patients are controversial. We conducted a study to compare the clinical significance of four markers in evaluating liver inflammation and fibrosis in CHB patients. METHODS: A total of 323 treatment-naive CHB patients who received a liver biopsy and routine laboratory testing were enrolled in our study. We used the Scheuer scoring system as a pathological standard for diagnosing liver inflammation and fibrosis. The diagnostic performance of the fibrosis index based on four factors (FIB-4), the aspartate transaminase to platelet ratio index (APRI), the gamma-glutamyl transpeptidase-to-platelet ratio (GPR), and the red cell distribution width-platelet ratio (RPR) were analyzed with receiver-operating characteristic curves (ROC). RESULTS: No significant differences among the four indexes for diagnosing significant fibrosis (S ≥ 2) was found, while APRI and GPR were superior to FIB-4 and RPR in diagnosing moderate (G ≥ 2), severe (G ≥ 3) inflammation, and severe fibrosis (S ≥ 3). The AUROCs for diagnosing G ≥ 2 and G ≥ 3 were 0.732 and 0.861 for APRI, 0.726 and0.883 for GPR, 0.703 and0.705 for FIB-4, and 0.660 and 0.747 for RPR, respectively. The AUROCs for diagnosing S ≥ 2 and S ≥ 3 were0.724 and 0.799 for APRI, 0.714 and0.801 for GPR, 0.683 and0.730 for FIB-4, and 0.643 and 0.705 for RPR, respectively. CONCLUSION: APRI and GPR were more effective than FIB-4 and RPR at diagnosing liver inflammation and fibrosis.
BACKGROUND: The benefits of using serum markers to diagnose stages of liver disease in chronic hepatitis B (CHB) patients are controversial. We conducted a study to compare the clinical significance of four markers in evaluating liver inflammation and fibrosis in CHB patients. METHODS: A total of 323 treatment-naive CHB patients who received a liver biopsy and routine laboratory testing were enrolled in our study. We used the Scheuer scoring system as a pathological standard for diagnosing liver inflammation and fibrosis. The diagnostic performance of the fibrosis index based on four factors (FIB-4), the aspartate transaminase to platelet ratio index (APRI), the gamma-glutamyl transpeptidase-to-platelet ratio (GPR), and the red cell distribution width-platelet ratio (RPR) were analyzed with receiver-operating characteristic curves (ROC). RESULTS: No significant differences among the four indexes for diagnosing significant fibrosis (S ≥ 2) was found, while APRI and GPR were superior to FIB-4 and RPR in diagnosing moderate (G ≥ 2), severe (G ≥ 3) inflammation, and severe fibrosis (S ≥ 3). The AUROCs for diagnosing G ≥ 2 and G ≥ 3 were 0.732 and 0.861 for APRI, 0.726 and0.883 for GPR, 0.703 and0.705 for FIB-4, and 0.660 and 0.747 for RPR, respectively. The AUROCs for diagnosing S ≥ 2 and S ≥ 3 were0.724 and 0.799 for APRI, 0.714 and0.801 for GPR, 0.683 and0.730 for FIB-4, and 0.643 and 0.705 for RPR, respectively. CONCLUSION: APRI and GPR were more effective than FIB-4 and RPR at diagnosing liver inflammation and fibrosis.
Authors: Yun Liao; Bei Cai; Yi Li; Jie Chen; Binwu Ying; Chuanmin Tao; Min Zhao; Zhu Ba; Zhaoxia Zhang; Lanlan Wang Journal: Liver Int Date: 2014-08-05 Impact factor: 5.828
Authors: W Ray Kim; Thomas Berg; Tarik Asselah; Robert Flisiak; Scott Fung; Stuart C Gordon; Harry L A Janssen; Pietro Lampertico; Daryl Lau; Jeffrey D Bornstein; Raul E Aguilar Schall; Phillip Dinh; Leland J Yee; Eduardo B Martins; Seng Gee Lim; Rohit Loomba; Jörg Petersen; Maria Buti; Patrick Marcellin Journal: J Hepatol Date: 2015-12-02 Impact factor: 25.083
Authors: Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad Journal: Hepatology Date: 2015-11-13 Impact factor: 17.425
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: W G Shin; S H Park; M K Jang; T H Hahn; J B Kim; M S Lee; D J Kim; S-Y Jun; C K Park Journal: Dig Liver Dis Date: 2007-12-04 Impact factor: 4.088
Authors: A J Hirsch Allen; Ali Abdul Ghafoor; Yu Liu; Andrew Sandford; Rachel Jen; Patrick Daniele; Carolyn Taylor; Bernardo U Peres; Najib T Ayas Journal: Sleep Breath Date: 2022-06-07 Impact factor: 2.816